B.AaslandO
Despite the considerable cost, the evidence presented to the NICE committee suggests this medicine is a cost-effective use of NHS resources for some patients
They act on multiple disease mechanisms simultaneously, including insulin resistance, hepatic steatosis, and chronic inflammation, thereby offering new hope to millions of patients living with progressive fatty liver disease
Peptide Vials (Tirzepatide, 10 mg each): 8 weeks (2.55 mg/wk): ~30 mg total 3 vials 12 weeks (2.57.5 mg/wk): ~60 mg total 6 vials 16 weeks (2.510 mg/wk): ~100 mg total 10 vials Insulin Syringes (U100, 1 mL): 8 weeks: 8 syringes (1/week) 12 weeks: 16 syringes (~1.3/week avg) 16 weeks: 24 syringes (~1.5/week avg) Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution
One promising real-world signal comes from fibromyalgia
Risks of Individual Cancers in the Pooled Tirzepatide versus Control (Pooled and Individual) Groups RR, risk ratio